Table 3.
mRNA-LNP-based vaccines for cancer and infectious disease in clinical trials
| Name | Condition | Clinical phase | Status | NCT No |
|---|---|---|---|---|
| mRNA-1345 | RSV | Phase I | Recruiting | NCT04528719 |
| Rabipur® | Rabies virus | Phase I | Active, not recruiting | NCT03713086 |
|
mRNA-1325 mRNA-1893 |
Zika virus |
Phase I Phase I |
Completed Completed |
|
| VAL-506440; mRNA-1440 | Influenza A virus [H10N8] | Phase I | Completed | NCT03076385 |
| VAL-339851; mRNA-1851 | Influenza A virus [H7N9] | Phase I | Completed | NCT03345043 |
| mRNA-1647 and mRNA-1443 | CMV | Phase I | – | NCT03382405 |
| SAM-LNP- Spike | COVID-19 | Phase I | Recruiting | NCT04776317 |
| SAM-LNP- Spike | COVID-19 | Phase I | Active, not recruiting | NCT04758962 |
| ChulaCov19 mRNA vaccine | COVID-19 | Phase I | Not yet recruiting | NCT04566276 |
| SARS-CoV-2 mRNA vaccine | COVID-19 | Phase III | Not yet recruiting | NCT04847102 |
| TAA mRNA | Melanoma | Phase I | Recruiting | NCT02410733 |
| TAA and neo‑Ag mRNA | Breast cancer | Phase I | Recruiting | NCT02316457 |
| mRNA-2752 | Solid tumors | Phase 1 | Recruiting | NCT03739931 |
| mRNA-2416 | Solid tumor, Lymphoma, and Ovarian | Phase I-II | Recruiting | NCT03323398 |
| mRNA-4157 | Bladder carcinoma and NSCLC | Phase I | Recruiting | NCT03313778 |
| mRNA-4157 | Melanoma | Phase II | Recruiting | NCT03897881 |